STANDARDS FOR THE SAFER USE OF ePMA SYSTEMS FOR USE IN SACT SERVICES
Published Feb 2022
The main purpose of this document is to improve safety to patients and maintain consistency throughout the UK. The document was first published by the BOPA in 2015 and updated in 2019. The current version has been extensively reviewed by representatives of the whole oncology workforce in the UK to reflect the multidisciplinary use of this document.
NATIONAL SACT PROTOCOLS OPTIONS APPRAISAL
Published Jan 2022
The UK Chemotherapy Board have produced this document to showcase a potential solution for the provision of national SACT protocols within the UK called the National SACT Protocol Programme
THE MANAGEMENT OF GLYCAEMIC CONTROL IN PATIENTS WITH CANCER - updated Sept 2021
Guidance for the diabetes and oncology multidisciplinary teams. Report of a working party on behalf of the UK Chemotherapy Board and Joint British Diabetes Societies for Inpatient Care.
CLINICIAN FAQS AND GUIDANCE ON COVID-19 VACCINE FOR PATIENTS RECEIVING SACT. VERSION 6.0.
Updated on website 21/12/21
This document has been produced in response to questions raised by cancer health care professionals relating to the administration of COVID-19 vaccines in patients receiving SACT.
PERSONALISED MEDICINE APPROACH FOR FLUOROPYRIMIDINE-BASED THERAPIES
To provide clinical staff with guidance as to which patients should receive a DPD test and then subsequently to provide advice to clinical staff on the outcome of that test.
MEDICATION-RELATED OSTEONECROSIS OF THE JAW: GUIDANCE FOR THE ONCOLOGY MULTI-DISCIPLINARY TEAM
This guidance has been produced by a multi-disciplinary working party on behalf of the UK Chemotherapy Board and endorsed by the Clinical Standards Committee of the Faculty of Dental Surgery of the Royal College of Surgeons of England. It focuses on all aspects of MRONJ in relation to oncology patients.
UK Chemotherapy board endorsement policy to guide professional organisations requesting endorsement for documents, policies, position statements or meetings.
GOOD PRACTICE GUIDELINE FOR IMMUNO-ONCOLOGY MEDICINES
This guideline is designed to give a practical framework for the safe introduction and ongoing use of immunotherapy in existing Systemic Anti-Cancer Therapy (SACT) services.
PROMOTING EARLY IDENTIFICATION OF SACT SIDE EFFECTS: TWO APPROACHES – GOOD PRACTICE GUIDELINE
Guidance was produced in response to concerns that patients often delay reporting serious SACT side effects. Two complementary approaches to improve side effect reporting are suggested.
MORBIDITY AND MORTALITY WITHIN 30 DAYS OF SACT - REVIEW OF CURRENT PRACTICE - STANDARDISED REVIEW PROCESS
The UK Chemotherapy Board recognised the many current examples of good practice but noted an inconsistency of approach between centres which may limit sharing of learning. It has summarised the key details of the processes currently used and developed a proposed template for an operational policy and pro forma.